Please assess the completion status of the following clinical trial:

Trial Title: ZS Ph2/3 Dose-response Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures.~* Patients aged ≥18. For patients aged \<20 years, a written informed consent should be obtained from the patient and his or her legally acceptable representative.~* Two consecutive i-STAT potassium values, measured 60 (± 10) minutes apart, both values should be ≥ 5.1 mmol/L and ≤ 6.5 mmol/L and measured within 1 day before the first dose of study drug on Study Day 1.~* Ability to have repeated blood draws or effective venous catheterization.~* Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.~Exclusion Criteria:~* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)~* Cause or symptoms of pseudohyperkalemia, such as~  1. hemolyzed blood specimen due to excessive fist clenching to make veins prominent~ 2. hemolyzed blood specimen due to difficult or traumatic venepuncture~ 3. history of severe leukocytosis or thrombocytosis~* Patients treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of study drug on Study Day 1~* Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate \[SPS; e.g. Kayexalate®\] or calcium polystyrene sulfonate \[CPS\]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug~* Patients with a life expectancy of less than 3 months~* Patients who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the patients' tasks associated with the protocol~* Female patients who are pregnant, lactating, or planning to become pregnant~* Patients who have an active or history of diabetic ketoacidosis~* Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof~* Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry~* Patients with cardiac arrhythmias that require immediate treatment~* Patients on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium Zirconium Cyclosilicate (ZS) 5g (Type: EXPERIMENTAL): Suspension administered 5g orally three times daily for 48 hours.
- Sodium Zirconium Cyclosilicate (ZS) 10g (Type: EXPERIMENTAL): Suspension administered 10g orally three times daily for 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo suspension administered orally placebo three times daily for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).